Background. Mini-host models are simple experimental systems to study host-pathogen interactions. We adapted a Drosophila melanogaster infection model to evaluate the in vivo effect of different mechanisms of linezolid (LNZ) resistance in Staphylococcus aureus.
, including those from a hospital outbreak of linezolid resistant S. aureus [17] .
The common approach to detect antibiotic resistance in clinical practice is based on the determination of minimal inhibitory concentrations (MICs), using conventional in vitro susceptibility tests. Although MIC determination is a very useful tool, there are limitations in drawing in vivo inferences from MICs, because outcomes in patients treated with a particular antibiotic may depend on other factors, such as differences in in vivo expression of resistance genes, the influence of the immune response on bacterial killing, and pharmacokinetic/ pharmacodynamic (PK/PD) parameters of a particular drug at the sites of infection [19] . The most tantalizing example of these limitations involves the ongoing controversy of vancomycin breakpoints and patient outcomes of MRSA infection [20] .
Based on the above rationale, the possibility of testing antimicrobial resistance using animal models emerges as an attractive alternative to evaluate the host-pathogen interaction. However, important limitations of using mammalian models for this purpose include costs, logistics, turnaround time, and ethical issues. Thus, nonmammalian models have been developed as surrogate hosts for evaluation of bacterial virulence and antimicrobial effectiveness [21] [22] [23] . The fruit fly Drosophila melanogaster is genetically well defined, has a short generation time, and possesses an innate immune system that is remarkably similar to that of humans [24] . Moreover, the D. melanogaster model has been used for the analysis of S. aureus pathogenesis, where inoculation results in systemic infection followed by death [25] [26] [27] . Previous studies have also shown that this mini-host model is useful for testing the therapeutic response to antifungals [28] [29] [30] . In this study, we assessed the in vivo effect of different mechanisms of LNZ resistance in S. aureus, using the mini-host model of D. melanogaster. We show that important differences in the in vivo therapeutic effect of LNZ are dependent on the specific mechanism of resistance, suggesting that D. melanogaster offers promise as a simple and cost-effective model for the in vivo evaluation of antimicrobial resistance.
METHODS

Bacterial Strains and Growth Conditions
Three LNZ-resistant clinical strains of S. aureus were evaluated (Table 1) : NRS119, which harbors the G2576T substitution in the 23S rRNA genes (all 5 copies) [7, 31] ; 004-737X, which carries the cfr gene on a plasmid (55 kb) [16] ; and CM05, which harbors cfr on the chromosome [10, 32] . S. aureus ATCC 29213 was also included as a LNZ-susceptible control. LNZ MICs were determined by the Etest. To assess the growth kinetics, bacterial strains were grown in trypticase soy broth (TSB). Overnight cultures were inoculated in TSB, and A 600 was assessed from 0 to 12 hours and at 24 hours.
Selection of LNZ-Susceptible Derivatives of S. aureus 004-737X and CM05 Lacking cfr
To obtain a susceptible derivative of 004-737X, which carries the cfr gene on a plasmid, we cured the cfr plasmid as described previously [33] . Individual colonies were screened by replica plating in Mueller-Hinton (MH) agar containing chloramphenicol (30 µg/mL) and LNZ (4 µg/mL). Additionally, we identified a derivative of CM05 that spontaneously lost the cfr gene, using replica plating of individual CM05 colonies in the presence and absence of LNZ and chloramphenicol, as described before [34] . LNZ-susceptible derivatives from both 004-737X and CM05 were characterized by polymerase chain reaction for detection of the cfr gene [15] , MIC determination by the Etest, pulsed-field gel electrophoresis (PFGE) [35] , and S1 nuclease digestion coupled with PFGE and hybridization with a cfr probe [36] .
D. melanogaster Infection Model
Wild-type Oregon R D. melanogaster flies were maintained using standard procedures for manipulation, feeding, and housing [37] . , and 500 µg/mL. Flies fed food without LNZ were included as a control in all experiments. Deaths resulting in the first 3 hours after infection were excluded from the survival analysis because they were likely to be caused by the inoculation procedure. Flies were incubated at 30°C, transferred to receive fresh food every 3 days, and monitored for 8 days. Three independent experiments were performed at each antibiotic concentration on different days and at the same time of the day, to eliminate circadian rhythmassociated variability.
Determination of LNZ Toxicity and Concentration in Flies
To determine whether LNZ is toxic to D. melanogaster, groups of 30 uninfected flies were fed with food supplemented with LNZ at concentrations of 500, 1000, and 2000 µg/mL and observed for 8 days. To estimate the concentration of LNZ in flies, groups of 300 female wild-type flies were fed with LNZ at concentrations of 0, 30, 60, 125, 250, and 500 µg/mL after a 6-hour starvation period. Subsequently (24 hours after feeding), flies were transferred to empty tubes, weighted, rinsed twice with sterile saline, and macerated in hybridization bags with 400 µL of sterile water. Fly homogenates were centrifuged for 3 minutes at 2348 × g. The supernatants were recovered and stored at −4°C while protected from light. A bioassay was carried out using S. aureus ATCC 25923, which was grown in MH broth to obtain a cell suspension of 1 × 10 8 CFU/mL and then diluted to 1 × 10 7 CFU/mL in MH broth. The bacterial suspension was then spread on MH agar plates and allowed to dry at ambient temperature. Full-thickness holes (6 mm in diameter) were punched in the agar. A total of 60 µL of supernatant from fly homogenates was placed in each well, and plates were incubated aerobically at 37°C for 24 hours. Diameters of circular inhibition zones that developed around the LNZcontaining wells were used to determine the LNZ concentration, using a linear regression model. Each determination was repeated 4 times.
Mouse Peritonitis Model
Female (age, 4-6 weeks), outbred ICR mice (Harlan Sprague Dawley, Houston, TX) were used as previously described [38] . S. aureus 004-737X, its susceptible derivative (004-737X cfrcured), and NRS119 were included in these experiments. Inoculation was performed by intraperitoneal injection of 1 mL of bacterial inoculum (2-4 × 10 9 CFU/mL) of the corresponding staphylococcal strains in a suspension containing 50% sterile rat fecal extract, as described previously [38] . Groups of 6 mice in each treatment arm and a group of 3 mice as an infection control were included. Survival was recorded 96 hours after infection. One hour after bacterial inoculations, mice were given LNZ at 80 mg/kg or 120 mg/kg every 12 hours via oral gavage, with treatment continuing for 7 doses on the basis of previously published mouse PK data that correlate with human dosage [39] [40] [41] . Surviving animals were euthanized 96 hours after inoculation. Kidneys and spleens were harvested and homogenized in saline. Colony counts on BHI agar from the homogenates were performed to determine bacterial densities in tissues. Experiments were approved by the Animal Welfare Committee, University of Texas Health Science Center at Houston.
Statistical Analysis
Bacterial growth curves were compared for the resistant strains and their susceptible derivatives, using an unpaired 2-tailed t test at each time point. Survival curves were plotted using Kaplan-Meier analysis and compared using the log-rank test. Survival rates were compared using the unpaired 2-tailed t test. The geometric mean log 10 CFU of bacteria recovered from kidneys and spleens were analyzed for statistical significance by analysis of variance with the Tukey post hoc test. The analyses were performed using GraphPad Prism, version 4.0 (GraphPad Software, San Diego, CA). Data were considered statistically significant if P values were < .05. Figure 1A shows that intrathoracic infection with S. aureus To assess the protective effect of LNZ, flies were initially fed food supplemented with LNZ at a final concentration of 500 µg/mL immediately after challenge with different strains of S. aureus, continued for 8 days. LNZ at the above concentration fully protected the flies against challenge by all strains regardless of susceptibility to LNZ (survival, 80%-95% at 8 days; P < .0001 for all strains, compared with survival in the absence of the antibiotic; Figure 1B ). These findings indicate that high concentrations of LNZ in flies were sufficient to overcome the in vivo effect of resistance, irrespective of the type of LNZ resistance.
RESULTS
LNZ Protects D. melanogaster Against S. aureus Infection
The In Vivo Effect of LNZ Resistance in D. melanogaster Is Dependent on Antibiotic Concentration and Mechanism of Resistance
Since we did not observe an in vivo effect of LNZ resistance with antibiotic concentrations of 500 µg/mL added as a supplement to the fly food, we subsequently tested descending amounts of the antimicrobial (250, 125, 60, 30, and 15 µg/mL). Concentrations as little as 15 µg/mL of LNZ in the food protected D. melanogaster against challenge by S. aureus ATCC 29213 (LNZ susceptible), with survival rates of >78% at 8 days (P < .0001, compared with infection in the absence of antibiotic; Figure 2A ). In contrast, LNZ at concentrations of 15-250 µg/mL failed to protect flies when challenged with NRS119 (MIC, 64 µg/mL), with survival rates ranging from 1.6% to 20% after 8 days of treatment ( Figure 2B) . Consistent with differences in MICs, the in vivo effect of cfr against LNZ was strikingly different from that observed with NRS119 (which harbors the mutational mechanism). Indeed, LNZ remained active against 004-737X (which harbors cfr on a plasmid; MIC, 8 µg/mL) at concentrations in food of ≥60 µg/ mL (survival rates, ≥80%; Figure 2C ). The in vivo effect of cfrmediated resistance was only observed at 30 and 15 µg/mL, with survival of 41% and 36%, respectively (P < .0001 for both values, compared with a concentration of 60 µg/mL [90% survival]). With CM05, which has only 1 chromosomal copy of cfr [32, 33] , resistance in vivo could only be identified at the lowest concentration tested (15 µg/mL in the fly food), with a survival rate of only 29% (P < .0001, compared with 30 µg/mL; Figure 2E ). Our findings indicate that cfr is less efficient at conferring resistance in vivo, compared with mutations in 23S rRNA.
To establish a direct correlation between the in vivo effect of LNZ against LNZ-resistant S. aureus carrying the cfr gene, we created LNZ-susceptible derivatives of S. aureus 004-737X and CM05 by curing the cfr plasmid and selecting cells lacking cfr, respectively. The genetic identities of the cfr-negative derivatives were confirmed by PFGE in both instances and by S1 digestion for 004-737X (Supplementary Figure 1A and 1B) . The loss of cfr did not affect the in vitro growth kinetics of the strains (Supplementary Figure 1C) , and, as shown in Table 1 , the loss of cfr reduced the LNZ MIC to levels below the susceptibility breakpoint, confirming the direct correlation between cfr and LNZ resistance. Moreover, LNZ at all concentrations protected all cfr-negative derivatives ( Figure 2D and 2F) , confirming that cfr only modestly affected the activity of LNZ in vivo.
Since the in vivo therapeutic effect of LNZ was dependent on the concentration used in the fly food, we developed a bioassay to estimate the amount of the drug in the insect bodies. Using a simple regression linear model constructed with LNZ standard solutions (Supplementary Figure 2) , we determined LNZ concentrations in the supernatant of fly homogenates. Table 2 shows the estimated concentrations of LNZ per insect (µg) and per fly homogenate (µg/mL). Our data suggest that the in vivo effect observed is due to the presence of LNZ in tissues and that LNZ is absorbed in D. melanogaster in a dose-dependent manner.
Comparison of the Mini-Host Model With a Murine Model of Peritonitis
To compare our mini-host model results with those from a mammalian model of infection, a mouse peritonitis model was used to assess the in vivo efficacy of LNZ against S. aureus 004-737X (MIC, 8 µg/mL), a cfr-cured derivative of 004-737X (MIC, 2 µg/mL), and NRS119 (MIC, 64 µg/mL). This model has been previously used to evaluate the response to LNZ therapy [40, 41] . The drug was administrated orally via gavage every 12 hours at doses of 80 mg/kg and 120 mg/kg, which, according to previous PK/PD studies, mimic human parameters ( peak serum concentrations of LNZ in humans after an oral dose of 600 mg are 15-27 µg/mL) [39] [40] [41] [42] . Figure 3 shows that all strains killed the host (100% mortality at 96 hours), using similar inocula in the absence of antibiotic. Mortality at 48 hours in mice infected with NRS119 was 100% as compared to 0% with 004-737X at similar inocula (P < .0001), suggesting a difference in virulence between the 2 strains in this model. Moreover, the loss of cfr increased the rate of killing of 004-737X, with mortality approaching 100% at 48 hours, suggesting that the cfr-containing plasmid (or other plasmids) may affect the in vivo fitness of the strain. Similar to the results reported above for Drosophila, cfr had no effect on survival at LNZ doses used in the mouse model. Indeed, both dose schemes protected all animals at 96 hours (100% survival). In contrast, the mutational mechanism of resistance present in NRS119 reduced the protection achieved by LNZ therapy, although the effect, as observed in the mini-host model, was concentration dependent ( Figure 3A) . The difference in the in vivo effect of the mechanisms of LNZ resistance was also observed in tissues ( Figures 3B  and 3C ). LNZ did not produce a significant decrease in colony counts in either spleen or kidney specimens when mice were infected with S. aureus NRS119. Interestingly, cfr carried by strain 004-737X produced only a weak in vivo effect against LNZ, since the antibiotic reduced bacterial densities in both organs at the tested doses, although the values did not reach statistical significance (P > .05). Notably, a significant decrease in bacterial counts in both organs at both dose schemes was observed after loss of the cfr-carrying plasmid from strain 004-737X ( Figure 3 ). Our findings suggest that the in vivo effect of the mechanisms of LNZ resistance is comparable between the D. melanogaster and mouse models.
DISCUSSION
Animal models to study host-pathogen interactions are important tools in the understanding of virulence and response to antimicrobial therapy. The use of small-mammal infection Figure 3 . In vivo effect of linezolid against S. aureus challenge in a mouse peritonitis model. A, survival curves using the three strains, 004-737X, its susceptible derivative (004-737X cfr cured) and NRS119. Inocula are shown in parenthesis. B, bacterial densities in kidney homogenates and C, bacterial densities in spleen homogenates. For B and C, data are expressed as log 10 CFU/mg, horizontal bars represent the geometric mean titers, which were compared by ANOVA with Tukey's post-hoc test. A P value of <.05 was considered significant. Abbreviations: CFU, colony-forming units; LNZ, linezolid.
models has important limitations, and thus invertebrate models have become popular tools for studying host-pathogen interactions [43] . D. melanogaster is an inexpensive model for the study of pathogenesis and antibiotic interactions of grampositive organisms, including Listeria monocytogenes [44] , Bacillus subtilus, staphylococci, Enterococcus faecalis, Streptococcus pneumoniae, and Streptococcus pyogenes [25, 28] . Moreover, D. melanogaster has a fully developed innate immune system comparable to that of mammals [24] , and organisms such as S. aureus are highly virulent in this model, with low survival rates in the first 48 hours after infection (bacterial inocula, 10 7 -10 9 CFU/mL) [25, 45, 46] . Indeed, using the Drosophila model, Needham et al were able to study S. aureus virulence and the effect of antibiotics such as methicillin and tetracycline, which can rescue flies from S. aureus infection [25] .
In this work, we adapted a D. melanogaster model to assess the efficacy of LNZ therapy and the in vivo effect of mechanisms of LNZ resistance. We aimed to dissect the in vivo role of 2 different mechanisms, namely, mutations in the 23S rRNA genes and Cfr-mediated resistance, which confer different levels of resistance in vitro, and to determine a correlation between our D. melanogaster model, MICs, and a mouse model. We chose LNZ since it is an important anti-S. aureus antimicrobial agent that can be administered orally with excellent bioavailability in humans. To determine the effect of LNZ against S. aureus infection in our mini-host model, we mixed fly food with the antibiotic and assessed the in vivo effectiveness of the drug. Of note, LNZ at 500 µg/mL mixed in the fly food fully protected D. melanogaster against S. aureus strains, including those that harbor well-characterized mechanisms of resistance, suggesting that high doses of the antibiotic in this model can overcome the mechanism without exhibiting overt toxicity. However, it is important to note that equivalently high linezolid levels in humans may have clinically important toxic effects on bone marrow. Lower concentrations of LNZ in food showed a clear in vivo difference between mutational and cfr-mediated mechanisms of LNZ resistance consistent with the MICs. Indeed, LNZ protection against NRS119, which harbors mutations in 23S rRNA genes (MIC, 64 µg/mL) was not seen at concentrations of ≤250 µg/mL in the fly food (survival at 8 days, <20%). Conversely, we only detected lack of LNZ protection in the cfr-carrying strains (with lower LNZ MICs) at reduced antibiotic concentrations (30 and/or 15 µg/mL in the food), indicating that the in vivo effect of cfr-mediated LNZ resistance is only evident at low concentrations of the antibiotic. Of interest, linezolid protected flies against CM05 at concentrations of 30 and 60 µg/mL, even though the amount of antibiotic detected in fly extracts was below the MIC for the organism. This could indicate that, even at subinhibitory concentrations, LNZ may have a protective effect against this strain. Alternatively, our assay may not correlate with actual concentrations in deep tissues at low doses.
To compare the in vivo effect of resistance in our mini-host model with that of a more established mammal model of infection, we used the mouse peritonitis model, which has been widely used in testing antibiotics [47] [48] [49] . We evaluated 2 LNZ regimens that had been previously shown to be effective in mice against intraperitoneal challenge with different S. aureus strains [39] [40] [41] 48] . Both doses of LNZ protected the animals from death after intraperitoneal challenge of the cfr-carrying S. aureus strain 004-737X, with 100% survival at 96 hours. Conversely, the effect of the resistance mechanism was evident in strain NRS119, with 50% and 100% mortality at 120 and 80 mg/kg, respectively. On the other hand, cfr-mediated resistance had no impact on survival in the mouse model, and a modest (albeit nonstatistically significant) reduction in CFU from tissues was observed. Thus, it is tempting to speculate that cfr may impact in vivo bacterial fitness and that LNZ may negatively affect the production of virulence determinants in S. aureus [50] , preventing progression to an inflammatory cascade that results in clinical symptoms.
The mini-host model is an easy, inexpensive, potentially high-throughput, and reproducible alternative to evaluate the in vivo resistance in S. aureus. However, it also has some limitations. First, the amount of LNZ absorbed cannot be precisely determined, and PK/PD determinations would be difficult to establish, although we showed that antibiotic concentrations in fly homogenates correlate with in vivo efficacy. Second, it seems likely that only oral antimicrobials would be evaluable in this model. Third, virulence determinants may target different cells in each model, and therefore the effect of the antibiotic may not be totally comparable. And fourth, despite the considerable similarities in innate immune mechanisms, invertebrate models are not directly comparable with mammalian models. Thus, it is reasonable to expect that some of the virulence attributes of S. aureus that affect mammals might not be important in the fly model. Nonetheless, we have shown striking similarities in the in vivo behavior of LNZ resistance mechanisms between our mini-host and murine models, which may possibility lead to use of D. melanogaster as a model for dissecting the in vivo effect of different mechanisms of antibiotic resistance in gram-positive pathogens.
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